Liq­uidia wins against Unit­ed Ther­a­peu­tics in patent bat­tle over PAH drug

Unit­ed Ther­a­peu­tics has suf­fered two court loss­es in its fight to keep a com­peti­tor for its block­buster drug Ty­va­so (tre­pros­tinil) from en­ter­ing the mar­ket, with fed­er­al judges rul­ing in fa­vor of Liq­uidia and the FDA in sep­a­rate cas­es last week.

Liq­uidia an­nounced Mon­day that a fed­er­al judge in Delaware got rid of a 2022 in­junc­tion that was part of a patent law­suit brought by Unit­ed Ther­a­peu­tics, fi­nal­ly al­low­ing the FDA to ap­prove Liq­uidia’s NDA for Yutrepia, its ver­sion of tre­pros­tinil, an in­haled pow­der that treats pul­monary ar­te­r­i­al hy­per­ten­sion (PAH). With ap­proval, Liq­uidia would be en­ter­ing a block­buster mar­ket: Unit­ed said in its lat­est earn­ings that Ty­va­so brought in $1.2 bil­lion in sales in 2023, a 41% in­crease over the pre­vi­ous year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER